PTC Therapeutics Appoints Ronald C. Renaud, Jr. to Board of Directors
SOUTH PLAINFIELD, N.J., June 11, 2014 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced the appointment of Ronald C. Renaud, Jr. to the company's Board of Directors. Mr. Renaud has served as the President and Chief Executive Officer of Idenix Pharmaceuticals, Inc., a public biopharmaceutical company, since October 2010.
"We are delighted to welcome Ron to PTC's Board of Directors. Ron brings tremendous skills and experience to PTC that will be invaluable to our future growth and success. His demonstrated leadership experience in building successful biotechnology companies, his former background as an equity research analyst and his deep knowledge of the life sciences industry will provide valuable contributions to our company," said Stuart W. Peltz, Ph.D., Chief Executive Officer, PTC Therapeutics, Inc.
Mr. Renaud previously served as the Chief Financial Officer of Idenix from the time he joined Idenix in June 2007 and was additionally appointed chief business officer in June 2010. Prior to joining Idenix, Mr. Renaud served as senior vice president and chief financial officer of Keryx Biopharmaceuticals, Inc., a biopharmaceutical company, from February 2006 to May 2007. He was a senior research analyst and global sector coordinator for JP Morgan Securities from May 2004 until February 2006, where he was responsible for the biotechnology equity research effort, covering all ranges of capitalized biotechnology companies. He also spent more than five years at Amgen, where he held positions in clinical research, investor relations and finance. Mr. Renaud holds a B.A. from St. Anselm College and an M.B.A. from the Marshall School of Business at the University of Southern California.
"I am thrilled to join PTC during this exciting time in the company's history," said Mr. Renaud. "I look forward to supporting the commercialization of Translarna™ in the EU, the advancement of Translarna™ in the US, as well as the continued growth and development of PTC's broad pipeline."
ABOUT PTC THERAPEUTICS, INC.
PTC is a biopharmaceutical company focused on the discovery and development of orally administered, proprietary small molecule drugs that target post-transcriptional control processes. Post-transcriptional control processes regulate the rate and timing of protein production and are essential to proper cellular function. PTC's internally discovered pipeline addresses multiple therapeutic areas, including rare disorders, oncology and infectious diseases. PTC has developed proprietary technologies that it applies in its drug discovery activities and in collaborations with leading biopharmaceutical companies. For more information on the company, please visit our website www.ptcbio.com.
FORWARD LOOKING STATEMENTS:
All statements, other than those of historical fact, contained in this press release, including statements regarding the future expectations, plans and prospects for PTC, the timing of regulatory approvals, the development of and potential market for Translarna, our ability to satisfy the obligations necessary to obtain full approval for Translarna in nmDMD, and the objectives of management, are forward-looking statements. Other forward-looking statements may be identified by the words "anticipate," "believe," "estimate," "expect," "intend," "may," "plan" "predict," "project," "target," "potential," "will," "would," "could," "should," "continue," and similar expressions. Our actual results, performance or achievements could differ materially from those expressed or implied by forward-looking statements we make as a result of a variety of risks and uncertainties, including among others, those related to our expectations for regulatory approvals, including the European Commission's determination with respect to conditional marketing authorization for Translarna in nmDMD, the initiation and conduct of clinical trials, availability of data from clinical trials, our scientific approach and general development progress, the availability or commercial potential of our product candidates, and the other factors discussed in the "Risk Factors" section of our most recent Quarterly Report on Form 10-Q, which is on file with the Securities and Exchange Commission. You are urged to carefully consider all such factors. In addition, any forward-looking statements included in this press release are as of the date of this release and PTC specifically disclaims any obligation to update such forward-looking statements, which should not be relied upon as representing PTC's views as of any date subsequent to the date of this press release.
SOURCE PTC Therapeutics, Inc.